Financhill
Sell
16

RCEL Quote, Financials, Valuation and Earnings

Last price:
$5.53
Seasonality move :
-1.26%
Day range:
$5.31 - $5.73
52-week range:
$5.31 - $14.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.01x
P/B ratio:
40.83x
Volume:
568K
Avg. volume:
345.5K
1-year change:
-36.1%
Market cap:
$146.4M
Revenue:
$64.3M
EPS (TTM):
-$2.19

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RCEL
AVITA Medical
$26.4M -$0.10 48.59% -59.98% $16.95
CATX
Perspective Therapeutics
$177.7K -$0.31 -- -55.87% $14.2692
RVP
Retractable Technologies
-- -- -- -- --
VNRX
VolitionRX
$881K -$0.05 6.24% -40.63% $2.93
VTAK
Catheter Precision
$310K -$0.20 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.2M -$0.01 4.73% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RCEL
AVITA Medical
$5.54 $16.95 $146.4M -- $0.00 0% 2.01x
CATX
Perspective Therapeutics
$3.1700 $14.2692 $235.3M -- $0.00 0% 22.34x
RVP
Retractable Technologies
$0.65 -- $19.5M -- $0.00 0% 0.58x
VNRX
VolitionRX
$0.64 $2.93 $65.5M -- $0.00 0% 43.82x
VTAK
Catheter Precision
$0.37 -- $4M 0.40x $0.00 0% 4.19x
XTNT
Xtant Medical Holdings
$0.62 $1.75 $86.7M -- $0.00 0% 0.70x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RCEL
AVITA Medical
112.39% -0.913 19.27% 1.65x
CATX
Perspective Therapeutics
-- -0.117 -- --
RVP
Retractable Technologies
1.48% -0.665 12.06% 4.40x
VNRX
VolitionRX
-29.91% 1.866 11.38% 0.34x
VTAK
Catheter Precision
17.75% -2.440 53.57% 0.13x
XTNT
Xtant Medical Holdings
43.24% 1.041 51.14% 0.96x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RCEL
AVITA Medical
$15.7M -$11.8M -102.9% -415.55% -68.15% -$10.5M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
RVP
Retractable Technologies
-$1.9K -$3.2M -25.99% -26.39% -122.86% -$1.6M
VNRX
VolitionRX
-- -$5.4M -- -- -2183.56% -$4.3M
VTAK
Catheter Precision
$132K -$3.5M -126.5% -137.84% -3300.7% -$2.3M
XTNT
Xtant Medical Holdings
$20.2M $1.1M -15.44% -26.62% 3.28% $87K

AVITA Medical vs. Competitors

  • Which has Higher Returns RCEL or CATX?

    Perspective Therapeutics has a net margin of -74.86% compared to AVITA Medical's net margin of --. AVITA Medical's return on equity of -415.55% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About RCEL or CATX?

    AVITA Medical has a consensus price target of $16.95, signalling upside risk potential of 205.92%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.2692 which suggests that it could grow by 350.13%. Given that Perspective Therapeutics has higher upside potential than AVITA Medical, analysts believe Perspective Therapeutics is more attractive than AVITA Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RCEL
    AVITA Medical
    3 1 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is RCEL or CATX More Risky?

    AVITA Medical has a beta of 1.547, which suggesting that the stock is 54.653% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.093, suggesting its more volatile than the S&P 500 by 9.29%.

  • Which is a Better Dividend Stock RCEL or CATX?

    AVITA Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AVITA Medical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RCEL or CATX?

    AVITA Medical quarterly revenues are $18.5M, which are larger than Perspective Therapeutics quarterly revenues of --. AVITA Medical's net income of -$13.9M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, AVITA Medical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AVITA Medical is 2.01x versus 22.34x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RCEL
    AVITA Medical
    2.01x -- $18.5M -$13.9M
    CATX
    Perspective Therapeutics
    22.34x -- -- -$18.2M
  • Which has Higher Returns RCEL or RVP?

    Retractable Technologies has a net margin of -74.86% compared to AVITA Medical's net margin of -126.59%. AVITA Medical's return on equity of -415.55% beat Retractable Technologies's return on equity of -26.39%.

    Company Gross Margin Earnings Per Share Invested Capital
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
    RVP
    Retractable Technologies
    -0.02% -$0.35 $77.8M
  • What do Analysts Say About RCEL or RVP?

    AVITA Medical has a consensus price target of $16.95, signalling upside risk potential of 205.92%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that AVITA Medical has higher upside potential than Retractable Technologies, analysts believe AVITA Medical is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    RCEL
    AVITA Medical
    3 1 0
    RVP
    Retractable Technologies
    0 0 0
  • Is RCEL or RVP More Risky?

    AVITA Medical has a beta of 1.547, which suggesting that the stock is 54.653% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.386, suggesting its more volatile than the S&P 500 by 38.583%.

  • Which is a Better Dividend Stock RCEL or RVP?

    AVITA Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AVITA Medical pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

  • Which has Better Financial Ratios RCEL or RVP?

    AVITA Medical quarterly revenues are $18.5M, which are larger than Retractable Technologies quarterly revenues of $8.3M. AVITA Medical's net income of -$13.9M is lower than Retractable Technologies's net income of -$10.5M. Notably, AVITA Medical's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AVITA Medical is 2.01x versus 0.58x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RCEL
    AVITA Medical
    2.01x -- $18.5M -$13.9M
    RVP
    Retractable Technologies
    0.58x -- $8.3M -$10.5M
  • Which has Higher Returns RCEL or VNRX?

    VolitionRX has a net margin of -74.86% compared to AVITA Medical's net margin of -2201.34%. AVITA Medical's return on equity of -415.55% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
    VNRX
    VolitionRX
    -- -$0.06 -$22.6M
  • What do Analysts Say About RCEL or VNRX?

    AVITA Medical has a consensus price target of $16.95, signalling upside risk potential of 205.92%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 362.44%. Given that VolitionRX has higher upside potential than AVITA Medical, analysts believe VolitionRX is more attractive than AVITA Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RCEL
    AVITA Medical
    3 1 0
    VNRX
    VolitionRX
    2 1 0
  • Is RCEL or VNRX More Risky?

    AVITA Medical has a beta of 1.547, which suggesting that the stock is 54.653% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.247%.

  • Which is a Better Dividend Stock RCEL or VNRX?

    AVITA Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AVITA Medical pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RCEL or VNRX?

    AVITA Medical quarterly revenues are $18.5M, which are larger than VolitionRX quarterly revenues of $246.4K. AVITA Medical's net income of -$13.9M is lower than VolitionRX's net income of -$5.4M. Notably, AVITA Medical's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AVITA Medical is 2.01x versus 43.82x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RCEL
    AVITA Medical
    2.01x -- $18.5M -$13.9M
    VNRX
    VolitionRX
    43.82x -- $246.4K -$5.4M
  • Which has Higher Returns RCEL or VTAK?

    Catheter Precision has a net margin of -74.86% compared to AVITA Medical's net margin of -2828.67%. AVITA Medical's return on equity of -415.55% beat Catheter Precision's return on equity of -137.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
    VTAK
    Catheter Precision
    92.31% -$0.36 $9.6M
  • What do Analysts Say About RCEL or VTAK?

    AVITA Medical has a consensus price target of $16.95, signalling upside risk potential of 205.92%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 447.95%. Given that Catheter Precision has higher upside potential than AVITA Medical, analysts believe Catheter Precision is more attractive than AVITA Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RCEL
    AVITA Medical
    3 1 0
    VTAK
    Catheter Precision
    0 0 0
  • Is RCEL or VTAK More Risky?

    AVITA Medical has a beta of 1.547, which suggesting that the stock is 54.653% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.850, suggesting its less volatile than the S&P 500 by 184.968%.

  • Which is a Better Dividend Stock RCEL or VTAK?

    AVITA Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AVITA Medical pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RCEL or VTAK?

    AVITA Medical quarterly revenues are $18.5M, which are larger than Catheter Precision quarterly revenues of $143K. AVITA Medical's net income of -$13.9M is lower than Catheter Precision's net income of -$4M. Notably, AVITA Medical's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AVITA Medical is 2.01x versus 4.19x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RCEL
    AVITA Medical
    2.01x -- $18.5M -$13.9M
    VTAK
    Catheter Precision
    4.19x 0.40x $143K -$4M
  • Which has Higher Returns RCEL or XTNT?

    Xtant Medical Holdings has a net margin of -74.86% compared to AVITA Medical's net margin of 0.18%. AVITA Medical's return on equity of -415.55% beat Xtant Medical Holdings's return on equity of -26.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
    XTNT
    Xtant Medical Holdings
    61.52% -- $77.3M
  • What do Analysts Say About RCEL or XTNT?

    AVITA Medical has a consensus price target of $16.95, signalling upside risk potential of 205.92%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 181.13%. Given that AVITA Medical has higher upside potential than Xtant Medical Holdings, analysts believe AVITA Medical is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    RCEL
    AVITA Medical
    3 1 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is RCEL or XTNT More Risky?

    AVITA Medical has a beta of 1.547, which suggesting that the stock is 54.653% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

  • Which is a Better Dividend Stock RCEL or XTNT?

    AVITA Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AVITA Medical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RCEL or XTNT?

    AVITA Medical quarterly revenues are $18.5M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. AVITA Medical's net income of -$13.9M is lower than Xtant Medical Holdings's net income of $58K. Notably, AVITA Medical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AVITA Medical is 2.01x versus 0.70x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RCEL
    AVITA Medical
    2.01x -- $18.5M -$13.9M
    XTNT
    Xtant Medical Holdings
    0.70x -- $32.9M $58K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Is TTD The Big Winner If Pharma Ads Are Banned?
Is TTD The Big Winner If Pharma Ads Are Banned?

Last week, Senators Bernie Sanders and Angus King introduced a…

Is Palantir Stock Overvalued?
Is Palantir Stock Overvalued?

By every traditional yardstick, including a price‑to‑sales well above 100,…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
11
VEON alert for Jun 14

VEON [VEON] is down 18.57% over the past day.

Buy
74
DAVE alert for Jun 14

Dave [DAVE] is down 12.68% over the past day.

Buy
54
DAR alert for Jun 14

Darling Ingredients [DAR] is up 9.12% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock